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Abstract
Background: Agonistic autoantibodies directed at the a1-adrenergic receptor (a1-AAB) have been described in patients with
hypertension. We implied earlier that a1-AAB might have a mechanistic role and could represent a therapeutic target.
Methodology/Principal Findings: To pursue the issue, we performed clinical and basic studies. We observed that 41 of 81
patients with refractory hypertension had a1-AAB; after immunoadsorption blood pressure was significantly reduced in
these patients. Rabbits were immunized to generate a1-adrenergic receptor antibodies (a1-AB). Patient a1-AAB and rabbit
a1-AB were purified using affinity chromatography and characterized both by epitope mapping and surface plasmon
resonance measurements. Neonatal rat cardiomyocytes, rat vascular smooth muscle cells (VSMC), and Chinese hamster
ovary cells transfected with the human a1A-adrenergic receptor were incubated with patient a1-AAB and rabbit a1-AB and
the activation of signal transduction pathways was investigated by Western blot, confocal laser scanning microscopy, and
gene expression. We found that phospholipase A2 group IIA (PLA2-IIA) and L-type calcium channel (Cacna1c) genes were
upregulated in cardiomyocytes and VSMC after stimulation with both purified antibodies. We showed that patient a1-AAB
and rabbit a1-AB result in protein kinase C alpha activation and transient extracellular-related kinase (EKR1/2)
phosphorylation. Finally, we showed that the antibodies exert acute effects on intracellular Ca2+ in cardiomyocytes and
induce mesentery artery segment contraction.
Conclusions/Significance: Patient a1-AAB and rabbit a1-AB can induce signaling pathways important for hypertension and
cardiac remodeling. Our data provide evidence for a potential clinical relevance for a1-AAB in hypertensive patients, and the
notion of immunity as a possible cause of hypertension.
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Introduction
Autoimmunity with agonistic autoantibodies directed at endog-
enous receptors can cause Graves’ disease through the thyrotropin
receptor and promotes insulin release via CD38 [1,2]. Agonistic
antibodies that stimulate the angiotensin (Ang) II AT1 receptor have
been described in preeclampsia and humorally mediated kidney
transplant rejection [3,4]. The most compelling case for agonistic
autoantibody-mediated disease has been that of b1-adrenergic
receptor autoantibodies observed in patients with dilated cardio-
myopathy and in a rat model fulfilling Koch’s postulates [5].
However, autoantibodies could also merely be an epiphenomenon
in many instances; convincing data are still pending.
a1-adrenergic receptor (a1-AR) signaling mediates several
cardiovascular actions such as vascular smooth muscle cell
(VSMC) contraction, cardiac inotropy, hypertrophy, and remod-
eling [6]. a1-AR are predominantly located postsynaptically on
VSMC, where they are the targets of circulating norepinephrine
and regulate VSMC contraction [7]. Sympathetic over-activity in
hypertension and accompanying excess stimulation of postsynaptic
a1-AR supports the use of selective a1-AR inhibitors as
antihypertensive drugs. However, a1-AR blockade was discontin-
ued in the Antihypertensive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial (ALLHAT) because of a putative
increased risk for heart failure [8], a highly controversial decision
that has been sharply criticized [9]. The Valsartan Heart Failure
Trial 2 (Val-HeFT2) showed that a1-AR blockade was beneficial
in heart failure. a1-AR can contribute to cardiomyocyte
hypertrophy. Huang et al demonstrated a protective effect of the
a1A-AR-subtype in cardiac myocytes and defined an extracellular-
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regulated kinase (ERK) signaling pathway that is required for
myocyte survival [10]. Hearts of a1-AR gene-deleted mice had
increased interstitial fibrosis, increased apoptosis, and failed
induction of the fetal hypertrophic gene program after pressure
overload, indicating that a1A-AR are required for myocardial
adaptation to stress [11,12].
Others and we have described agonistic autoantibodies (a1-
AAB) against the a1-AR [13,14,15]. Earlier, we examined
immunoglobulin fractions in 54 severely hypertensive patients
and found a1-AAB in 44% [15]. However, 12% of normotensive
control subjects also harbored a1-AAB. Zhou et al. immunized rats
with a peptide from the a1-AR epitope [16]. The rats developed
a1-AR antibodies (a1-AB) and cardiac hypertrophy. However, the
link between a1-AB formation and cardiac remodeling remains
unclear. We have now performed additional studies to elucidate
the pathophysiological relevance of a1-AAB. We show that
removal of a1-AAB with immunoadsorption is feasible and lowers
blood pressure. We raised a1-AB in rabbit and purified the a1-AB
from rabbits and a1-AAB from patients by affinity chromatogra-
phy. After confirming binding and functional specificity of the
isolated rabbit a1-AB and human a1-AAB, we performed gene
expression analysis in cardiomyocytes and vascular smooth muscle
cells (VSMC). We show that both rabbit a1-AB and human a1-
AAB can evoke calcium signaling and contract vessel preparations
via protein kinase C alpha (PKC-a) activation and transient
extracellular-related kinase (ERK 1/2) phosphorylation. Our data
suggest that human a1-AAB can induce signaling pathways
involved in hypertension and cardiac remodeling, suggesting a
potential clinical relevance of a1-AAB.
Results
We analyzed a1-AAB in 81 patients with refractory hyperten-
sion, who required $3 antihypertensive medications. Severe
hypertension-induced target organ damage was present in every
patient, including funduscopic changes, cardiac abnormalities, and
kidney damage. Fourty-one patients (51%) featured a1-AAB as
assessed by cardiomyocyte contraction assay. Microalbuminuria
was detected in 33%, diastolic dysfunction in 87%, left ventricular
(LV) hypertrophy in 85%, and reduced ejection fraction in 13% of
a1-AAB positive patients. The patient characteristics are outlined
in Table 1.
Figure 1 shows data from the five a1-AAB positive patients
undergoing immunoadsorption. The treatments were performed
daily for 5 days. The cardiomyocyte contraction assay document-
ed gradually decreasing a1-AAB activity during the course of the
five immunoadsorptions (Figure 1A, B). At the end of five days, the
activity was in the normal range. The decreased a1-AAB activity
persisted for the 180 day observation period (Figure 1C). Blood
pressure recordings performed before and after 5 days of
treatment showed a significant reduction in mean arterial pressure
(MAP), compared to initial values that remained significantly
reduced for the observation period of 180 days (Figure 1D).
a1-AAB were directed against the first extracellular loop (eL1) in
24% and against the second extracellular loop (eL2) in 27% of the
hypertensive patients (Figure 2A). Epitope mapping for the first and
second extracellular loop of the a1A-AR by cardiac contraction
assay is shown in Figure 2B and C. Overlapping peptide sequences
were tested for competition in cardiac contraction assay. For
extracellular loop 1 (eL1) the peptide sequence P1 (YWAFGR)
diminished the spontaneous beating rate response completely. The
peptide sequence P2 (APEDET) competed for the antibody
extracellular loop 2 (eL2) effect. Since activating autoantibodies
against the second loop have already been described for the AT1-R
and b1-AR receptor, we analyzed a1-AAB against the second
extracellular loop of a1A-AR in this study.
We purified a1-AAB from patients by affinity chromatography
using the peptide of the second extracellular loop of the a1A-AR.
We then used surface plasmon resonance (SPR) measurements to
determine the binding affinity and specificity of purified
autoantibody fractions. Sensorgrams, depicted in Figure 3,
demonstrate that the antibodies displayed a high binding affinity
(Kd,50 nM) to the biotinylated peptide corresponding to eL2 of
the a1-AR immobilized to the SA-sensorchip. This affinity-purified
antibody fraction also showed weak cross-reactivity with the
biotinylated peptide corresponding to the eL1 of the a1-AR
(Figure 3A). However, this binding was negligible compared to the
strong eL2 interaction.
We next raised a peptide antibody against the second extracellular
loop of the a1-AR (rabbit a1-AB) and purified the antibody on the
same peptide-containing affinity matrix. In SPR experiments, the
rabbit a1-AB produced regular association and dissociation kinetics
reaching a signal of ,2500 RU at a concentration of 80 mg/ml
(Figure 3B). Purified a1-AAB from patients and rabbit a1-AB
increased the beating rate of rat cardiomyocytes. This effect was dose-
dependent (Figure 3C andD). Themaximal response was obtained at
an antibody dilution of 1:200 (0.5 and 0.6 mg/ml medium,
respectively). The positive chronotropic effect was blocked by the
a1-AR antagonist prazosin (1 mM).
To elucidate the molecular pathways induced by a1-AAB, we
performed gene expression studies. We used Affymetrix microarrays
for quantification of mRNA expression in cardiomyocytes and
VSMC after treatment with purified a1-AAB isolated from three
different patients, rabbit a1-AB, human control IgG, and the a1-AR
agonist phenylephrine (PE) for 24 h. We identified two genes with
increased expression in the Affymetrix array that we then verified by
TaqMan RT-PCR. These genes were PLA2-IIA and Cacna1c, as
shown in Table 2. The upregulation of both genes was inhibited by
the a1-AR antagonist prazosin while no changes in gene expression
were observed after the treatment with the control IgG.
We tested whether or not a1-AAB from patients and rabbit a1-
AB could elicit Ca2+ signals. Figure 4A shows the reaction of
neonatal cardiomyocytes intracellular Ca2+ transients in response
to the addition of the purified patient a1-AAB. There was a fast
increase in the 340 nm/380 nm ratio, which peaked at less than
60 seconds and declined within 2 minutes to a plateau value
Table 1. Clinical features of the patients classified as a1-AR-
AA positive or negative.
a1-AAB Positive Negative
Number 41 40
Age range 46–81 years 42–81 years
Male 59% 60%
Female 41% 40%
Medication classes 4.3 4.7
Goal blood pressure 77% 76%
Heart failure 64% 57%
Reduced ejection fraction 13% 24%
Diastolic dysfunction 87% 81%
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slightly above the control level before the addition of the a1-AAB.
Thus, a1-AAB potently induced a rise in intracellular Ca
2+ in the
targeted neonatal cardiomyocytes. To elucidate whether or not
this Ca2+ response could be common to an autoantibody-a1-AR
loop 2-type interaction, we used a rabbit a1-AB. As shown in
Figure 4B, this rabbit a1-AB also generated an acute positive Ca
2+
response in the cardiomyocytes with a similar time course as did
the human antibody preparation. These responses were not
elicited by a control IgG. As illustrated in Figure 4C, an IgG
prepared from an a1-AAB negative patient was not able to raise
the intracellular Ca2+.
These results prompted myographic experiments in mesenteric
arteries displayed in Figure 5. Treatment with KCl documented
brisk viability of the preparation. PE and the rabbit a1-AB both
Figure 1. Effects of immunoadsorption on a1-AAB and blood pressure. (A) Ordinate shows neonatal cardiomyocyte spontaneous beating
rate; abscissa shows response to immunoadorption performed on a representative patient. The a1-AAB activity decreased with every
immunoadsorption with a total decrease in response over time. (B) Figure shows the initial spontaneous beating rate (closed circles). After five
immunoadsorptions, this response is reduced to basal values (open circles) in all 5 patients. (C) Mean response of a representative patient in
cardiomyocyte contraction assay over time to immunoadsorption is shown. (D) Mean arterial pressure (MAP) was measured 5 and 180 days after
immunoadsorption. MAP was significantly reduced compared to before immunoadsorption.
doi:10.1371/journal.pone.0003742.g001
Figure 2. Epitope mapping for extracellular loop 1 and loop 2 of a1A-AR is given. (A) a1-AAB were directed against the first extracellular
loop (eL1) in 24% and against the second extracellular loop (eL2) in 27% of the hypertensive patients. (B) The peptide sequence P1 (YWAFGR) and P2
(GRVFCNI) (partially) for eL1 were able to diminish the spontaneous beating rate response completely. (C) Epitope mapping for loop 2 is given for the
following amino acid sequences: P1: GWRQPA, P2: APEDET, P3: TICQIN, P4: INEEPG, P5: GYVLFS. The sequence P2 (APEDET) was able to diminish the
spontaneous beating rate response completely.
doi:10.1371/journal.pone.0003742.g002
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were able to constrict the vessel (Figure 5A). The effect of a1-AAB
from two patients and from rabbit a1-AB was compared to half-
maximal and maximal effective PE dosages, producing 50% and
100% of vessel constriction. Patient a1-AAB and rabbit a1-AB
showed marked vasoconstriction activity. Control IgG from
human and rabbits had no effect (Figure 5B).
We then examined signal transduction. We concentrated on
PKC-a and ERK 1/2 as both have been shown to be important in
a1-AR-stimulated hypertension-induced target organ damage [6].
As shown in Figure 6, we found that a1-AAB and rabbit a1-AB
exposure to cardiomyocytes or VSMC resulted in PKC-a
activation, as did the positive PE control. These effects were
blocked completely by the specific PKC-a blocker, Go¨ 6976.
Additionally, the incubation of Chinese hamster ovary (CHO) cells
stably transfected with human a1A-AR (CHO/a1A-AR) with a1-
AAB resulted in PKC-a activation, which was blocked by the
peptide P2, corresponding to the binding site of the a1-AAB
(Figure 7A).
We then studied ERK 1/2 phosphorylation and the upstream
phosphatidylinositol 3 (PI3)-kinase activity in CHO/a1A-AR cells.
Incubation with human a1-AAB resulted in ERK 1/2 phosphor-
ylation. The PI3-kinase inhibitor, LY294002, inhibited the ERK
1/2 phosphorylation (Figure 7B). Additional hypertensive patients,
who were either a1-AAB positive or negative in cardiomyocyte
contraction assay, were characterized by ERK 1/2 activation with
immunoblotting (Figure 8). a1-AAB from three patients induce a
transient ERK 1/2 phosphorylation similar to that evoked by PE
and rabbit a1-AB in neonatal cardiomyocytes. Phosphorylation
was blocked by prazosin (Figure 8A). A similar activation was
obtained in CHO/a1A-AR cells. The activation was specifically
blocked by peptide P2 (Figure 8B). Fractions eluted from patients,
who were negative in the cardiomyocyte contraction assay, failed
to activate ERK 1/2.
Figure 3. Binding and agonistic activity of patient a1-AAB and rabbit a1-AB. Surface plasmon resonance sensorgrams depicting antibody
binding to a1-AR peptides (A and B). Biotinylated peptide corresponding to the a1A-AR extracellular loop2 (eL2) were immobilized. A corresponding
peptide to extracellular loop1 (eL1) served as negative control. a1-AAB from a patient with refractory hypertension (A) and rabbit a1-AB (B) bind
exclusively to eL2. Note that the characteristics of the human antibody (A) and rabbit antibody (B) were the same. (C) Functional effects
(cardiomyocyte contraction assay) of affinity-purified a1-AAB (0.1–1 mg/ml medium) against second extracellular loop from a patient with refractory
hypertension and (D) rabbit a1-AB (0.12–1.2 mg/ml medium) against second extracellular loop. The functional findings corroborate the BIAcor results.
doi:10.1371/journal.pone.0003742.g003
Table 2. Differential expression of PLA2-IIA and Cacna1c in
cardiomyocytes and VSMC after treatment with patient a1-
AAB, rabbit rabbit a1-AB or PE (Fold changes in TaqMan
analysis).
a1-AAB rabbit a1-AB PE
PLA2-IIA
Cardiomyocytes 2.3 6.2 4.0
VSMC 4.8 2.5 5.1
Cacna1c
Cardiomyocytes 2.2 1.7 4.0
VSMC 2.0 1.8 2.2
doi:10.1371/journal.pone.0003742.t002
a1-AR Autoantibodies
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Discussion
The important findings in this study are that isolated a1-AAB und
generated a1-AB show similar binding characteristics by surface
plasmon resonance sensorgram and functional testing. The
antibodies induce a Ca2+ dependent signal transduction cascade
in VSMC and cardiomyocytes that are both important to the
pathophysiology of hypertension and cardiac remodeling. By gene
array studies, we showed that the isolated patient a1-AAB and
rabbit a1-AB both upregulate two gene types, namely PLA2-IIA and
Cacna1c. In a proof-of-concept, non-controlled trial, we show that
removal of a1-AAB by immunoadsorption lowers blood pressure in
a1-AAB positive patients with intractable primary hypertension.
The entire idea of ‘‘agonistic’’ autoantibodies contributing to
cardiovascular disease is controversial [17]. Antibodies directed at
receptors can block or stimulate their targets. Hallmark example of
the latter action is Graves’ disease where antibodies directed at the
thyroid stimulating hormone receptor exert an agonistic action.
Recently, compelling evidence has been presented regarding
agonistic antibodies directed against the a1-AR, the b-ARs, the
Ang II AT1-R, and the platelet-derived growth factor-alpha
receptor, as reviewed elsewhere [17]. The antibodies could play a
pathogenic role in various cardiovascular diseases, including
hypertension, cardiomyopathy, preeclampsia, acute humoral
rejection, and connective tissue disease.
Earlier, we speculated that a1-AAB could contribute to
hypertension [15]. Our goal here was to give the notion of a1-
AAB a more robust scientific basis. Thus, we verified our candidate
by generating a1-AB by immunization. Concomitantly, we
subjected patients from our collective who harbored a1-AAB to
immunoadsorption. We found in our uncontrolled trial that
lowering a1-AAB titers was associated with a lower blood pressure.
We did not perform a randomized double blind, crossover trial.
Nonetheless, our study meets class I (safety) criteria and suggests that
a future class II (efficacy) trial might be warranted. We cannot
exclude the possibility that short-term effects of the immunoad-
sorption, such as circulating blood volume changes during apheresis
or other confounders contributed to the reduction in blood pressure.
Since the reduction in blood pressure persisted for the observation
period of 180 days, we believe that removal of a1-AAB by apheresis
was the main cause for the blood pressure reduction. Within the five
days immunoadsorption period, the level of a1-AAB decreased
gradually. Thereafter, a1-AAB could not be detected after successful
immuoadsorption in these patients for the entire observation period
Figure 4. Representative traces of responses in intracellular Ca2+ of cultivated neonatal rat cardiomyocytes exposed to isolated
patient a1-AAB and rabbit a1-AB are shown. (A) a1-AAB isolated from the serum of a patient with refractory hypertension elicited a Ca
2+ signal.
(B) The rabbit a1-AB gave a similar Ca
2+ signal. (C) A human control IgG preparation was unable to affect intracellular Ca2+. Cardiomyocytes were
electrically stimulated at 1 Hz, and the peak Ca2+ was monitored.
doi:10.1371/journal.pone.0003742.g004
Figure 5. Contractile effect of patient a1-AAB and rabbit a1-AB in mesenteric arteries is given. A brisk KCl response is documented. (A)
Representative experiment showing the contractile response to phenylephrine (PE, 10 nM–10 mM) and rabbit a1-AB (50 mg in 5 ml PBS buffer). The
PE and antibody responses were similar in kind. (B) Contractile response of human a1-AAB isolated from two patients (5 mg in 5 ml PBS buffer) and
rabbit a1-AB (50 mg in 5 ml PBS buffer) are compared to the PE response (300 nM and 10 mM, respectively) is shown. Contractions are expressed as %
KCl response from patient 1 and patient 2. The human antibody responses were less than the low and high-dose PE responses. The rabbit a1-AB
responses approached the PE responses. Two columns on the right are control human and control rabbit IgG showing no response.
doi:10.1371/journal.pone.0003742.g005
a1-AR Autoantibodies
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of 180 days. A similar state-of-affairs has been described for b1-AAB
in dilated cardiomyopathy after immunoadsorption. These data
suggest that immunomodulation by removal or neutralization of the
AAB might represent a potential therapeutic strategy [18].
We isolated the detected a1-AAB and the a1-AB that we generated
against the same epitope in rabbits, using the same affinity
purification protocol. Since we used the same peptide sequence for
epitope mapping in the cardiomyocyte contraction assay, immuni-
zation in the rabbit, and isolation in the affinity column, we are
confident that we isolated solely a1-AB. Before using this material to
learn more about a1-AR signaling in VSMC and cardiomyocytes, we
confirmed binding specificity by functional (cardiac contraction assay
and ERK 1/2 phosphorylation) and biochemical (surface plasmon
resonance measurement) verification methods. We then performed
an Affymetrix gene expression study. We followed up on the results to
pursue two candidate genes, PLA2-IIA and Cacna1c that were
upregulated in the display, as verified by RT-PCR. Both genes
contribute to signaling pathways in hypertension and atherosclerosis.
Phospholipases A2 are acute-phase reactants and play an important
role in digestion and metabolism of phospholipids, as well as in
production of precursors for inflammatory reactions. Plasma PLA2-
IIA levels are increased in systemic inflammation, including,
rheumatoid arthritis and cardiovascular diseases [19,20,21]. In
infarcted hearts, expression of PLA2-IIA was markedly increased in
damaged cardiomyocytes [22]. Inhibition of PLA2-IIA also prevent-
ed cardiac fibrosis in spontaneously hypertensive rats [23].
Another important finding accrued is the fact that both the a1-
AAB from patients and the rabbit a1-AB affected intracellular Ca
2+ at
two different levels, namely the acute, short-term elevation of
intracellular Ca2+, and the increased transcript expression of the
voltage-gated L-type Ca2+ channel pore subunit. Acute administra-
tion of the purified antibodies to neonatal cardiomyocytes produced a
typically shaped Ca2+ transient. The onset of the cytosolic Ca2+
response occurred within few seconds reaching its maximum at less
than one minute. a1-AR stimulation potentiates L-type Ca
2+ current
through CaMK II activation in rat ventricular myocytes [24].
Figure 6. Protein kinase C alpha (PKC-a) activation in
cardiomyocytes and vascular smooth muscle cells (VSMC)
after 2 min incubation with PE, a1-AAB from patients, and
rabbit a1-AB is demonstrated. Horizontal rows show regimens,
namely, untreated control, PE, patient a1-AAB, and rabbit a1-AB. Vertical
columns show cardiomyocyte and VSMC responses. Yellow shows PKC-
a activation; red is more intense activation. Go¨ 6976 is a PKC-a inhibitor,
which blocked all responses.
doi:10.1371/journal.pone.0003742.g006
Figure 7. PKC-a and ERK 1/2 activation in CHO cells stably transfected with human a1A-AR (CHO/a1A-AR) by a1-AAB is
demonstrated. (A) Incubation of CHO/a1A-AR cells with a1-AAB for 2 min resulted in a PKC-a activation, which was blocked by the peptide P2, but
not by the peptide P5. (B) ERK 1/2 phosphorylation after incubation with a1-AAB for 5 min is shown. Inhibition of the upstream phosphatidylinositol
3 (PI3)-kinase activity by the inhibitor LY294002 strongly reduced ERK 1/2 phosphorylation. Yellow shows PKC-a and ERK 1/2 activation, respectively;
red is more intense activation.
doi:10.1371/journal.pone.0003742.g007
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Furthermore, rabbit antibody to the a1AR and autoantibodies
against the AT1-receptor could activate the Ca2+ current [25,26].
The peak response of cytosolic Ca2+ to the antibodies apparently
comprises a temporary imbalance of Ca2+ entry through L-type Ca2+
channel and the sarcoplasmic reticulum Ca2+ release on one hand
and Ca2+ sequestration into the sarcoplasmic reticulum and Ca2+
extrusion via the Na+/Ca2+ exchanger on the other hand.
In addition to acute Ca2+ current stimulation, we found that long-
term activation of the a1-AR pathway by patient a1-AAB and rabbit
a1-AB increases transcript levels of the voltage-dependent L-type
Ca2+ channel a1C subunit (Cacna1c) in neonatal cardiomyocytes
and VSMC. Voltage-dependent L-type Ca2+ channels (L-VDCC)
play a crucial role in the regulation of heart rhythm and contractile
performance, as well as in smooth muscle tone. The channels open
in response to membrane depolarization providing Ca2+ ingress into
the cell. In the myocardium, this local rise in Ca2+ concentration
triggers massive Ca2+ release from the sarcoplasmic reticulum stores
inducing in turn contraction. L-VDCC expressed in cardiac and
smooth muscle are multi-subunit proteins containing the a1C, a2/
d, and b subunits. The a1C subunit forms the ion-selective pore,
determines voltage sensitivity, and is a binding site for clinically used
Ca2+ channel blockers [27]. Thus, upregulation of a1C subunit
expression in response to a1-AR stimulation observed herein
provides the route for an enhanced Ca2+ ingress which may
contribute to Ca2+ imbalances and translate in cardiac dysfunction.
Our results are consistent with those of Pignier et al. who reported on
increased expression of functional L-type Ca2+ channels and
hypertrophy in neonatal cardiomyocytes upon chronic a1-AR
stimulation [28]. In contrast, Maki et al. described that in neonatal
rat cardiomyocytes activation of the a1-AR pathway was accom-
panied by attenuated a1C mRNA levels [29]. A link between
increased a1C protein levels and hypertrophy has also been
demonstrated for the human heart [30].
A transgenic mouse with cardiac specific over-expression of
solely the Ca2+ channel pore subunit has been studied intensively
[31]. When a1C protein levels were increased by about 3-fold, a
slightly increased Ca2+ inward current (30–40%) was observed,
and the mice developed hypertrophy and severe cardiomyopathy
as a function of age. The small sustained ingress of Ca2+ through
the channel is capable of elevating PKC-a before the development
of hypertrophy. [32] Activation of PKC in adult cardiomyocytes
regulates ERK 1/2 through the c-RAF/MEK/ERK signaling
pathway and a1-AR-stimulated hypertrophy in cardiomyocytes is
mediated via activation of the Ras-Raf-MEK1/2-ERK 1/2
signaling pathway [6,33]. As a consequence, we investigated the
regulation of PKC-a and ERK 1/2 activity by human a1-AAB,
rabbit a1-AB, or PE. We demonstrated that a1-AAB and a1-AB
induced PKC-a stimulation and ERK 1/2 phosphorylation.
Finally, we showed that human a1-AAB and the rabbit a1-AB
evoke vasoconstriction in a vascular bed.
Taken together, we present data from a limited, uncontrolled,
human trail of a1-AAB removal from severely hypertensive human
subjects. This trial presents a hypothesis-generating result. We
show that isolated a1-AAB from man and rabbits cause gene
upregulation important to hypertension-relevant pathways and
then document the induction of Ca2+-dependent pathways. We
provide evidence that a1-AAB are of potential pathophysiological
relevance and could represent a factor contributing to the
development of refractory hypertension. Removal or neutraliza-
tion of a1-AAB might represent a possible therapeutic option.
Accordingly, we suggest that the entire gamut of autoimmunity in
chronic cardiovascular disease warrants further critical inspection.
Materials and Methods
Patients
Patients requiring three or more medication classes to achieve
goal control blood pressure values were recruited from the Franz-
Volhard Clinic outpatient department. All had been studied
intensively and secondary causes of hypertension had been ruled
out. Home and clinic blood pressures in these patients were
determined with an automated oscillometric device under stan-
dardized conditions. The internal review board approved the study
and written informed consent was obtained from all participants.
Five patients harboring a1-AAB were asked to undergo five
immunoadsorption treatments with an especially prepared column
according to procedures described elsewhere [34].
a1-AAB detection
We isolated immunoglobulin fractions from serum samples as
described earlier [4,15]. For detection of autoantibodies, the
immunoglobulin fractions were added to neonatal rat cardiomy-
ocytes at a dilution of 1:20. For the neutralization experiments,
synthetic peptides corresponding to the sequence of the first
extracellular loop (YWAFGRVFCNIWA), and the second extra-
cellular loop (PAPEDETICQINEE) of the human a1A-AR were
each added in excess (0.05 to 0.1 mg) to the immunoglobulin
fraction. The mixtures were shaken and placed in a refrigerator for
1 h. The 100 ml samples were then added to neonatal rat heart
muscle cells cultured in 2 ml of medium to a final dilution of 1:40.
The beating rate was counted for 15 sec, 5 and 60 min after the
addition of the peptide/immunoglobulin mixture. We tested a1-
AAB activity in a neonatal cardiomyocyte assay without and with
Figure 8. Activation of ERK 1/2 in response to treatment with
PE, a1-AAB from patients or rabbit a1-AB is shown. (A)
Cardiomyocytes were treated for 5 and 15 min with 10 mM PE,
2.5 mg/ml a1-AAB or rabbit a1-AB, respectively. Equivalent amounts of
protein were analyzed by Western blotting with anti-pERK 1/2 antibody
(44/42 kD) and the amount of ERK was analyzed with anti-ERK 1/2
antibody. PE, patient a1-AAB, and rabbit a1-AB caused ERK 1/2
phosphorylation. (B) CHO/a1A-AR cells were incubated with patient
a1-AAB for 5 min. Lane 1 and 2 represent untreated cells. Patients 1, 4–8
were a1-AAB-positive in the cardiomyocyte contraction assay. ‘‘Patient’’
9 represents a pool of five a1-AAB positive patients. Patients 10–12 were
a1-AAB negative in the cardiomyocyte contraction assay. Their serum
samples were processed identically to those of a1-AAB-positive
patients. ERK 1/2 phosphorylation was inhibited by peptide P2, but
not by peptide P5. Eukaryotic initiation factor 4E (elF4E, 25 kD) antibody
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peptide inhibition. Pulsation rate was exhibited 1 h or 24 h,
respectively after incubation with a1-AAB and compared with the
spontaneous basal pulsation rate. Eight synchronously contracting
cell clusters per flask were counted for 15 sec on a heat table stage.
a1-AB generation in rabbit and antibody purification
We immunized rabbits against a peptide corresponding to the
amino acid sequence of the second extracellular loop of the
isoform A of human a1-AR (PAPEDETICQINEE) by BioGenes
GmbH (Berlin, Germany). The corresponding peptide of the
second extracellular loop of the a1-AR was covalently bound to e-
aminocapryl agarose (Sigma-Aldrich, Munich, Germany) to yield
epitope-specific affinity beads. For coupling the agarose gel matrix
(,1 ml of packed gel) was activated by glutaraldehyde (1%
solution, freshly prepared) for 20 min at room temperature on a
rotating wheel. The activated gel was extensively washed with PBS
and allowed to react with the peptide solution for 3 h at room
temperature or overnight at 4uC on a rotating wheel. The
coupling reaction was terminated by incubation with 200 mM
Tris/Glycine buffer pH 7.2. The affinity beads were poured into a
column (Bio-Rad, Munich, Germany) and stored with 0.02%
sodium acid in buffer A consisting of 50 mM Tris/HCl, 0.5 M
NaCl, pH 7.4, at 4uC.
The affinity beads were washed with buffer A to remove the
sodium acid. Serum samples (5–15 ml) from patients with
refractory hypertension or from immunized rabbits were incubat-
ed with the affinity beads overnight at 4uC on a rotating wheel.
The beads were allowed to settle and the sera were removed and
stored for a second round of affinity purification at a given matrix.
The beads were washed with buffer A until baseline levels of
protein are detected at 280 nm. The antibodies were eluted at
room temperature in 1 ml fractions with 50 mM Tris/Glycine,
0.5 M NaCl, pH 2.5. Antibody fractions were immediately
neutralized with 0.5 ml of 0.5 M Tris/HCl, 0.5 M NaCl,
pH 7.4. The antibody concentration was calculated by measure-
ment the absorption at 280 nm.
Surface plasmon resonance measurements
Binding experiments were performed in a BIAcore 2000
Instrument (Uppsala Sweden) at 25uC. N-terminally biotinylated
peptides corresponding to the first and second extracellular loop of
the a1A-AR were immobilized at binding levels of 100 relative
units (RU) each on parallel lanes of a SA-biosensor chip. Affinity-
purified antibodies from patient blood samples were injected in the
flow cells at a rate of 20 ml/min in HBSE running buffer consisting
of 10 mM HEPES, pH 7.4, 150 mM NaCl, and 3 mM EDTA.
The binding was regenerated between binding measurements
using 5 mM Tris/Glycine, 50 mM NaCl, pH 2.5, with no
decrease in extent measurements over the duration of an
experiment. Data were analyzed using the using the BIAevaluation
3.2 RC 1 program. The analysis software corrects for baseline drift
during measurements. The curves were fitted to a single-site
interaction model. Kd values were calculated by using the formula
Kd= koff /kon in which koff and kon is the rate constant of
dissociation and association kinetics, respectively.
Cell culture and autoantibody incubation
Rat neonatal cardiomyocytes were prepared from ventricles of 1–2
day-old Wistar rats using a modified method [35]. The cells were
cultured as monolayers for 4 days at 37uC in SM 20-1 medium
supplemented with 10% heat-inactivated calf serum, 2 mM fluor-
odeoxyuridine and penicillin/streptomycin. Aortic VSMC were
isolated from Sprague Dawley rats as described previously [36].
CHO cells were stably transfected with human a1A-AR (CHO/a1A-
AR) using a pSW104 vector and were cultured in F12 HAMmedium
supplemented with glutamine, 10% FCS and 1% penicillin/
streptomycin as described earlier [37]. For gene expression analysis
cardiomyocytes and VSMC, respectively were incubated with human
control IgG endobulin (5 mg/ml medium, Baxter, Wien, Austria), a1-
AAB from different patients (2.5 mg/ml medium), rabbit a1-AB
(2.5 mg/ml medium), and with the a1-AR agonist PE (10 mM, Sigma-
Aldrich) for 24 h in DMEM medium containing 1% serum.
Experiments were repeated with three different cardiomyocytes and
VSMC preparations. For investigation of protein phosphorylation,
cardiomyocytes and CHO/a1A-AR cells were maintained in serum-
free media for 24 h or 4 h, respectively and treated with PE, human
a1-AAB or rabbit a1-AB for 5 and 15 min, respectively. For
inhibition experiments, prazosin (1 mM, Sigma-Aldrich) was added.
Five mg of the peptides P2 (APEDET) or P5 (GYVLFS) were given to
2.5 mg of a1-AAB 1 h before cell treatment. For the inhibition of
ERK 1/2 activation, CHO/a1A-AR cells were pre-incubated with
PI3-kinase inhibitor LY294002 for 10 min.
Gene expression analysis
We extracted total RNA from cardiomyocytes treated with
human control IgG, a1-AAB, rabbit a1-AB or PE using the
RNeasy Purification Kit (Qiagen GmbH, Hilden, Germany).
RNA was treated by deoxyribonuclease I (Qiagen). Two mg RNA
of cells were transcribed in cRNA with One-Cycle Target labeling
and Control Reagents (Affymetrix, Santa Clara, CA, USA). Non-
pooled microarray experiments were performed with cRNA
prepared from independent cardiomyocyte cell preparations using
Rat Genome 230 2.0 Arrays (31,099 probe sets, Affymetrix). After
passing the quality control for each experiment a set of RMA
normalized expression values have been produced. The log scale
robust multi-array analysis (RMA) estimates are based upon a
robust average of log2 (B (PM)), where B (PM) are background
corrected perfect match intensities [38]. For statistical comparison
of expression data student’s t-test was used.
Quantitative Real-Time Reverse Transcriptase PCR
(TaqMan)
cDNA was synthesized from 2 mg of total RNA isolated from
cardiomyocytes and VSMC, respectively using PowerScript
Reverse Transcriptase (BD Bioscience Clontech, Palo Alto, USA)
and an Oligo (dT)18 primer. Real-time PCR experiments were done
using the Mx3000PH real-time PCR system (Stratagene Europe,
Amsterdam, NL) and the Brillant QPCR master mix (Stratagene
Europe). Real-time PCR was performed with non-pooled samples
from cardiomyocytes and VSMC respectively. Beta-2-microglobu-
lin (B2M) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were used as endogenous references to normalize expression of a
target gene. For every sample three independent runs in triplicates
and the relative changes in gene expression were quantified by
comparative Ct method [39]. Primer sequences are listed in Table 3.
Immunocytochemistry
We described the techniques for confocal microscopy and
immunocytochemistry as referenced previously [4,40]. The cells
were fixed with 4% paraformaldehyde and permeabilized with 80%
methanol at 220uC. After incubation with 2% BSA in PBS for
60 minutes, the preparation was incubated for 1 hour at room
temperature with the monoclonal anti-PKC-a antibody from UBI
(clone M4) diluted in PBS with 1% BSA (1:80) or pERK 1/2
antibody (1:200, Cell Signaling Technology, Boston, MA, USA),
respectively, washed twice with PBS, and then exposed to the
secondary antibody (Alexa-488-conjugated anti-mouse IgG at 1:200,
a1-AR Autoantibodies
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1% BSA/PBS; Invitrogen, Life Technologies, Carlsbad, CA, USA)
for 60 minutes. The preparation was mounted with AquaPolymount
(Polyscience, Niles, IL, USA) under a glass coverslip on a Nikon-
Diaphot microscope. An MRC 1024 confocal imaging system (Bio-
Rad) with an argon/krypton laser was used. At least 25 to 40 cells
from each of at least three experiments were examined under each
experimental condition.
Western blotting
Cardiomyocytes and CHO/a1A-AR cells were scraped in lysis
buffer [20 mM HEPES (pH7.9), 350 mM NaCl, 20% glycerol,
1 mM MgCl2, 0.5 mM EDTA, 0.1 mM EGTA, 1% NP40,
complete protease inhibitor cocktail (Roche Diagnostic GmbH,
Mannheim, Germany) and phosphatase inhibitor cocktail (Sigma-
Aldrich)] and centrifuged at 10,000 rpm for 10 min. Protein
concentrations were measured with Bradford method and equal
amounts of proteins were analyzed by Western blotting. ERK
phosphorylation was detected by pERK 1/2 antibody (1:1000, Cell
Signaling Technology). As translational control an ERK antibody
(1:1000, Cell Signaling Technology) and eukaryotic initiation factor
4E (elF4E) antibody (1:7000, Cell Signaling Technology) were used.
HRP-conjugated goat anti-rabbit secondary antibody (1:5000,
Jackson Immunoresearch Europe, Suffolk, UK) was used. Detection
was performed with the ECLTM-substrate (Lumigen, Southfield, MI,
USA) according to the manufacturers instructions.
Measurement of cytosolic Ca2+ transients
Neonatal cardiomyocytes were plated onto Labtek four chamber
slides (Nunc GmbH & Co, Wiesbaden, Germany) suited for
fluorescence measurements at a densitiy of 0.26106 cells per
chamber. After cultivation for four days the medium was removed
and cells were washed twice with 10 mMHepes-buffered Hank’s salt
solution, pH 7.4 (HBSS). Cardiomyocytes were incubated on HBSS
for 60 minutes at 37uC. Then the solution was replaced by 0.5 ml
HBSS containing 2.5 mM final concentration of Fura 2-AM
(Calbiochem AG, Luzern, Switzerland) and left for loading in the
dark at room temperature. After 30 min the loading solution was
aspirated, the cells washed and kept on 0.5 ml HBSS in the dark and
at room for another 30 minutes before use. Measurements of
cytosolic Ca2+ transients were performed on an IonOptix Fluores-
cence and Contractility System (Milton, MA, USA) equipped with a
Leica microscope with a heatable stage. All measurements were
carried out at 37uC. Cardiomyocytes were electrically stimulated at
1 Hz and the ratio of 340 nm/380 nm was recorded. After
stabilization of the Fura signal the control trace was taken. Antibody
preparations were applied in a constant volume of 100 ml of pre-
warmed HBSS to give a final concentration of 2 mg/ml. For
evaluation of Ca2+ changes peak values were derived from the trace
recordings representing the maximum cytosolic Ca2+ achieved in the
contracted cell.
Contraction of mesenteric arteries
Vessel rings from superior mesenteric arteries of male Sprague-
Dawley rats (200 to 300 g, 6 to 8 weeks) were prepared and
intracellular membrane potential was measured as earlier
described [41]. In the first series of experiments, the rings were
exposed to increasing doses of PE (10 nM–10 mM) and with
acetylcholine (10 nM–10 mM) for relaxation. Following, vessel
rings were incubated with a1-AAB (5 mg in 5 ml PBS buffer),
rabbit a1-AB (50 mg in 5 ml PBS buffer), rabbit IgG (50 mg in 5 ml
PBS buffer, Dunn Labortechnik GmBH, Asbach, Germany) and
human control IgG endobulin (50 mg in 5 ml PBS buffer).
Statistics
We relied on student’s t-tests (adjusted as necessary) for
normally distributed data and performed analysis of variance
(repeated measures were indicated). P,0.05 was accepted as
significant. Data are expressed as mean6SD.
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